Infliximab-induced headache and infliximab-induced meningitis: Two ends of the same spectrum?

Southern Medical Journal

Volumn 98, Issue 5, 2005, Pages 564-566

  Hegde, Nikita ^a   Gayomali, Charina ^a   Rich, Michael W ^a,b  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b Department of Medicine ^*  (United States)

Author keywords

Aseptic meningitis; Crohn's disease; Headache; Infliximab; Serum sickness

Indexed keywords

AMPICILLIN; CEFOTAXIME; FLUCONAZOLE; INFLIXIMAB; METHYLPREDNISOLONE; PREDNISONE; SULBACTAM; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; VANCOMYCIN;

ADULT; ANAMNESIS; ARTHRALGIA; ARTICLE; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CROHN DISEASE; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; FEMALE; FEVER; HUMAN; MENINGISM; MENINGITIS; MYALGIA; PLEOCYTOSIS; RISK FACTOR; SERUM SICKNESS;

ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; HEADACHE; HUMANS; MENINGITIS, ASEPTIC; MIDDLE AGED; SERUM SICKNESS;

EID: 18844402879     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.SMJ.0000155499.21189.75     Document Type: Article

References (11)

1. Remicade. Physician's Desk Reference. Montvale, NJ: Thomson PDR, 2004, pp 1145-1148.
2. Marotte H, Charrin JE, Miossec P. Infliximab-induced aseptic meningitis. Lancet 2001;358:1784.
3. Moris G, Garcia-Monco JC. The challenge of drug-induced aseptic meningitis. Arch Intern Med 1999;159:1185-1194.
4. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomized trial. Lancet 2002;359:1541-1549.
5. Hanauer SB, Rutgerts PJ, d'Haens G, et al. Delayed hypersensitivity to infliximab reinfusion after 2-4 year interval without treatment. Gastroenterology 1999;116:G3174.
6. Baert F, Nomati M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-608.
7. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone pre-medication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003;124:917-924.
8. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients. Gastroenterology 2004;126:19-31.
9. Bowie VL, Snella KA, Gopalachar AS, et al. Listeria meningitis associated with infliximab. Ann Pharmacother 2004;38:58-61.
10. Bergstrom L, Yocum DE, Ampel NM, et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum 2004;50:1959-1966.
11. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-1104.